Aro Biotherapeutics adds Valo Health executive Dr. Brett Blackman to its board, leveraging his extensive background in drug discovery and corporate operations to support its siRNA development pipeline.
Appointment of an experienced biotech executive to the board is a governance event with no immediate financial or operational impact.
Clinical-stage biotech firm Aro Biotherapeutics has appointed Dr. Brett Blackman to its Board of Directors. Blackman, currently serving as COO and CBO at Valo Health, brings over 25 years of experience in drug discovery and corporate strategy to the Philadelphia-based company.
Dr. Brett Blackman, who currently serves as the Senior Vice President, Chief Operating Officer, and Chief Business Officer at Valo Health.